Medicines & Supplements A to Z > Obinutuzumab

Obinutuzumab

Last updated on 14/07/2021.

Overview   |   Dosage   |    Side Effects   |   Precautions   |   Tips   |   Where To Buy  

GENERIC NAME: Obinutuzumab

CHINESE NAME: 阿托珠單抗

BRAND NAME(S) IN HONG KONG: Gazyva

DRUG CLASS: Antineoplastics

SUB CLASS: Monoclonal antibodies

USED FOR: Targeted cancer therapy, Chronic lymphocytic leukaemia, Treatment of follicular lymphoma

AVAILABLE DOSAGE FORMS:
– 1000mg/40mL (solution for infusion)

What is Obinutuzumab for?

Obinutuzumab is a type of monoclonal antibody. It is a type of targeted therapy to treat chronic lymphocytic leukaemia (CLL) and follicular lymphoma (FL).

How to use it?

Obinutuzumab is infused intravenously. Premedication is required 30-60 minutes prior to treatment, including Paracetamol, an antihistamine, and either Dexamethasone or Methylprednisolone. 

For previously untreated chronic lymphocytic leukaemia:
Treatment duration is 6 cycles, which one cycle consists of 28 days.
Cycle 1:
Day 1: 100 mg
Day 2: 900 mg
Day 8: 1000 mg
Day 15: 1000 mg
Cycles 2-6:
Day 1: 1000 mg every 28 days 

For previously untreated follicular lymphoma:
Option 1: Treatment duration is 6 cycles, which one cycle consists of 28 days, in combination with Bendamustine.
Cycle 1:
Day 1: 1000 mg
Day 8: 1000 mg
Day 15: 1000 mg
Cycle 2-6:
Day 1: 1000 mg every 28 days 

Option 2: Treatment duration is 6 cycles, which one cycle consists of 21 days, in combination with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone, followed by two additional cycles of Obinutuzumab alone.
Cycle 1:
Day 1: 1000 mg
Day 8: 1000 mg
Day 15: 1000 mg
Cycle 2-6:
Day 1: 1000 mg every 21 days
Cycle 7-8 (Obinutuzumab as monotherapy):
Day 1: 1000 mg every 21 days

Option 3: Treatment duration is 8 cycles, which one cycle consists of 21 days, in combination with Cyclophosphamide, Vincristine, and Prednisone.
Cycle 1:
Day 1: 1000 mg
Day 8: 1000 mg
Day 15: 1000 mg
Cycle 2-8:
Day 1: 1000 mg every 21 days

Option 4: For patients with stable disease, complete response, or partial response after 6 or 8 cycles of combination therapy should continue on Obinutuzumab as monotherapy for up to 2 years beginning around 2 months after the last dose of the last cycle.
– 1000 mg every 2 months for up to 2 years

For relapsed or refractory follicular lymphoma:
Option 1: Treatment duration is 6 cycles, which one cycle consists of 28 days, in combination with Bendamustine.
Cycle 1:
Day 1: 1000 mg
Day 8: 1000 mg
Day 15: 1000 mg
Cycle 2-6:
Day 1: 1000 mg every 28 days

Option 2: For patients with stable disease, complete response, or partial response after 6 cycles of combination therapy should continue on Obinutuzumab as monotherapy for up to 2 years beginning around 2 months after the last dose of the last cycle.
– 1000 mg every 2 months for up to 2 years

What are the side effects of Obinutuzumab?

Common side effects of Obinutuzumab include infusion-related reactions (such as dizziness, nausea, fever, vomiting), neutropenia, cough, fatigue, infection, and diarrhea.

Who should not take Obinutuzumab?

People who are allergic to Obinutuzumab or any component of the formulation.

Pharmacist Tips:

– Use effective contraception to avoid pregnancy during therapy and for at least 6 months after the last dose.
– If you have a history of hepatitis B, please inform your doctor before using this drug.
– This drug may cause hepatitis. Seek medical help immediately if you have symptoms such as worsening fatigue or yellow discoloration of skin or eyes.
– This drug may cause a serious brain problem. Seek medical help immediately if you have symptoms such as confusion, dizziness or loss of balance, difficulty talking or walking, or vision problems.

Common dosing schedule:
N/A. 

This schedule is for reference only, adjustments may be made according to individual needs.

Some common medications Obinutuzumab may interact with:
– Vaccine

Please notify your doctor or pharmacist if you are taking the above medication, dosage adjustments might be needed.

Where to buy Obinutuzumab in Hong Kong?

In Hong Kong, Obinutuzumab is a prescription only medicine, and requires a prescription from a doctor to be purchased in a pharmacy. It can also be obtained from doctors. To find a pharmacy near you, refer to the list of pharmacies (“Authorized Sellers of Poisons”) from the Hong Kong Department of Health.

For more information about drug names and ingredients, you can visit Hong Kong’s Drug Office at https://www.drugoffice.gov.hk

For more information about drug names and ingredients, you can visit Hong Kong’s Drug Office at https://www.drugoffice.gov.hk

Disclaimer: our goal is to provide you with the most relevant drug information and common dosage for Hong Kong. This information does not constitute medical advice. For specific treatment recommendations and advice, always discuss with your doctor or pharmacist, and follow the instructions included with your specific medicine.